We make analytics accessible
Analytics, software, and research in support of commercial operations for the life sciences industry.
We make analytics accessible.
Analytics, software, and research in support of commercial operations for the life sciences industry.
Services

sales force effectiveness
Optimize your sales force to increase sales with sizing, people mapping, call plan management incentive compensation (IC) planning and more.

market research
Maximize launch effectiveness and product success with qualitative and quantitative evidence-based support for commercial decision-making.

HEOR
Drive insights around epidemiology, burden of illness, medication utilization, and comparative effectiveness.

advanced analytics
Create and optimize brand messaging and allocation of resources to increase sales, customer satisfaction, and business outcomes.

data services
Implement enterprise-level data enrichment solutions to derive customer insights, inform smarter business decisions, and increase sales.
case studies
We solve problems and provide insights for our pharmaceutical clients. Here are some examples of recent projects.

Innovative Patient Simulation App to Explore Treatment for Rare Disease
To prepare for the launch of a novel therapy, our client needed to better understand the treatment algorithm for a rare disease condition. Our mid-size specialty pharmaceutical client needed to understand the treatment algorithm for a rare disease condition in...

Leverage Anonymized Patient Level Data (APLD) to Identify Market Opportunities
How can you use patient level data to help rebound from a sluggish product launch?Our client, a growing specialty pharmaceutical company, has a new product approved for treating two different diseases. After a year on the market, however, the new drug’s uptake is not...

Real World Evidence to Support Payer Negotiation
How do you prove a product's value to negotiate pricing with a payer? Our client, a large global pharmaceutical company, was facing a market access problem for their newly launched product. Generic treatments have been widely available for many years in this...
kmk insights
Innovative Patient Simulation App to Explore Treatment for Rare Disease
To prepare for the launch of a novel therapy, our client needed to better understand the treatment algorithm for a rare disease condition. Our mid-size specialty pharmaceutical client needed to understand the treatment algorithm for a rare disease condition in...
Leverage Anonymized Patient Level Data (APLD) to Identify Market Opportunities
How can you use patient level data to help rebound from a sluggish product launch?Our client, a growing specialty pharmaceutical company, has a new product approved for treating two different diseases. After a year on the market, however, the new drug’s uptake is not...
[Webinar Invite] Weathering the COVID-19 Storm: Incorporating Beliefs, Knowledge, and Research to Boost Confidence in Pharmaceutical Sales Forecasting
Weathering the COVID-19 Storm: Incorporating Beliefs, Knowledge, and Research to Boost Confidence in Pharmaceutical Sales Forecasting In this webinar, KMK Consulting, Inc. will share real-world approaches to forecasting and market research to more accurately predict...
HEOR Principal Huanxue Zhou’s Manuscript in International Journal of MS Care
KMK HEOR Principal Huanxue Zhou's latest manuscript has been published. The title of the article is Impact of Switching to Fingolimod Versus Injectable Disease-Modifying Therapy Cycling on Risk of Multiple Sclerosis-Related Relapses. A PDF of the article is available...
Real World Evidence to Support Payer Negotiation
How do you prove a product's value to negotiate pricing with a payer? Our client, a large global pharmaceutical company, was facing a market access problem for their newly launched product. Generic treatments have been widely available for many years in this...
What Innovations are Oncologists Looking Forward to in Breast Cancer Therapy?
KMK Consulting’s Innovation and Customer Value Survey in breast cancer explores oncologists’ perspectives on the innovations they are looking forward to in the next two years, and the companies they see as best positioned to deliver them. To learn more view the...